Public policy and advocacy
Novartis actively participates in public policy debates affecting healthcare and our business. We believe we have a responsibility to share our perspective, scientific knowledge, technical expertise and fact-based information with policymakers and regulatory authorities.
We strive to engage in constructive dialogue with government and others to improve health and preserve incentives for research and innovation. We work closely with trade associations, which create opportunities to raise industry standards and exchange best practice. We work closely with trade associations to foster framework conditions conducive to improving patient outcomes and investment into R&D. In 2014, Novartis Group companies supported various major trade associations with donations totaling USD 27 million.
Novartis Group companies maintain full-time public affairs offices in Basel, Switzerland; Brussels, Belgium; and Washington D.C., in the United States. We have additional public affairs personnel in many other countries, who assess regulatory and political decisions that may affect Novartis.
Some countries allow and even encourage contributions to support political organizations, candidates for public office and advocacy for public policy. Novartis makes political contributions in these countries, all of which must strictly comply with all laws, regulations and industry codes.
Novartis is included in Register of Interest Representatives, the European Commission’s voluntary self-regulation system, which aims to increase transparency of political contributions. Novartis has committed to publish an estimate of the costs associated with direct lobbying of the EU institutions incurred by in-house lobbyists and subscribe to the Commission’s Code of Conduct or a comparable professional code.
Novartis also actively participates in the US political process, where corporations typically support candidates by forming employee political action committees (PACs).